LANSING, Mich., Jan. 7, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that the Company will participate in two upcoming investor conferences.
The Company will participate in the CJS Securities 25th Annual Investor Conference, held virtually on January 14, 2025.
John Adent, Neogen's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on January 15, 2025, at 3:45 PM PT.
To access the webcast and presentation materials for the J.P. Morgan Healthcare Conference, please visit the Events & Presentations section of the Neogen Investor Relations website at neogen.com/investor-relations/events-presentations and click on the event webcast link.
About Neogen
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Media Contact
Bill Waelke, Vice President, IR & Treasury
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.39 |
| Daily Change: | -0.21 -4.57 |
| Daily Volume: | 12,316,827 |
| Market Cap: | US$952.370M |
January 21, 2025 January 10, 2025 December 17, 2024 October 10, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
